July 30, 2018 NEW YORK – ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotech company focused on transforming chemotherapy induced nausea and vomiting (CINV) outcomes through transdermal patch technology, today announced a strengthening of its Board and Management team. Andy Rensink joins the Company as Chief Manufacturing Officer, Hemal Shah joins as Health Economics and Outcomes Advisor, and Eric Baum joins the Company’s Board of Directors.
“The strength and depth of our pipeline and rapid development pace are being made possible by the addition of best in class support. Andy Rensink will lead our transition from the preclinical setting into Manufacturing, and Hemal Shah is adding incredible insights into the value our products will create by addressing the significant unmet medical need in the CINV setting” said Pedro Lichtinger, Chairman and CEO. “Our Board is also strengthened by the addition of Eric Baum who has rich experience financing and advancing emerging Companies; with his addition we now have three independent directors an important step in positioning the company for a successful IPO.”
Read more here.
